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Abstract
Background: In countries with a high burden of HIV, such as South Africa, where the epidemic remains the world’s
largest, improving early uptake of and consistent adherence to antiretroviral therapy could bring substantial HIV
prevention gains. However, patients are not linked to or retained in care at rates needed to curtail the epidemic.
Two strategies that have demonstrated a potential to stem losses along the HIV care cascade in the sub-Saharan
African context are use of text messaging or short message service (SMS) and peer-navigation services.
Methods/Design: We designed a cluster randomized trial to assess the efficacy of an SMS intervention and a
peer-navigation intervention to improve retention in care and treatment, timely linkage to care and treatment,
medication adherence, and prevention behaviors in South Africa. Eighteen primary and community healthcare
clinics in Rustenburg and Moses Kotane Sub-districts in the North West Province were randomized to one of three
conditions: SMS intervention (n = 7), peer navigation intervention (n = 7), or standard of care (n = 4). Approximately
42 participants are being recruited at each clinic, which will result in a target of 750 participants. Eligible
participants include patients accessing HIV testing or care in a study clinic, recently diagnosed with HIV, aged
18 years or older, and with access to a cellular telephone where they are willing to receive automated SMS with
HIV-related messaging. Data collection includes extraction of visit information from clinical files and participant
surveys at baseline, 6 months, and 12 months. Intent-to-treat (ITT) analysis will explore differences between
randomization arms and the primary outcome of patient retention in care at 12 months following enrollment. We
will also explore secondary outcomes including participants’ a) timely linkage to care (within 3 months of HIV
diagnosis), b) adherence to treatment based on self-report and clinic’s medication dispensation dates, and c)
condom-use behaviors.
Discussion: The findings will allow us to compare the efficacy of two complementary interventions, one that
requires fewer resources to implement (SMS) and one (peer navigation) that offers more flexibility in terms of the
patient barriers to care that it can address.
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Background
The success of “treatment-as-prevention” trials has ush-
ered in a new era in worldwide HIV prevention efforts
[1]. Antiretroviral therapy (ART) suppresses viral repli-
cation, effectively forestalling disease progression and re-
ducing the likelihood of viral transmission [2–6]. The
landmark HPTN 052 trial among HIV sero-discordant
couples found that early ART initiation (when CD4+ cell
count is between 350 and 500 cells/μL) can reduce HIV
transmission to uninfected partners by 96 % [2]. In
countries with a high burden of disease, such as South
Africa, where the epidemic remains the world’s largest
with an estimated 6.4 million people living with HIV
(PLHIV) [7], improving early uptake of and adherence
to ART could bring substantial gains in HIV prevention.
Modeling suggests that annual HIV testing with the im-
mediate initiation of ART (at any CD4 count) in South
Africa could reduce HIV incidence and mortality to less
than one case per 1000 people per year by 2016 [8].
Additionally, South Africans residing in communities
with greater ART coverage have a lower risk of HIV ac-
quisition [9]. While instituting universal ART coverage
will be challenging to implement in resource-
constrained settings, important gains can be attained by
ensuring that infected individuals are identified early in
their HIV disease, enter into care rapidly, and remain in
care and adherent to their regimens following the initi-
ation of treatment. Unfortunately, in sub-Saharan Africa,
some 40 % of individuals who test positive are not suc-
cessfully linked to care, and only 50 % of those who are
not yet ART-eligible are retained in HIV care [10], lead-
ing to a “cascade” of losses at each stage along the care
continuum [11].
In South Africa, the government continues to sponsor
national HIV testing campaigns and has expanded ART
eligibility, first to those with a CD4+ cell count of 350
cells/μL or less and recently to those with a CD4+ cell
count of 500 cells/μL or less [12, 13]. Although treat-
ment expansion is critical, current losses along the HIV
care cascade are impeding HIV prevention gains. Na-
tional data from 2012 indicated that 65 % of the popula-
tion had been tested for HIV; however, only 37.8 % of
HIV-positive men and 55 % of HIV positive women were
aware of their HIV status [7]. Additionally, once diag-
nosed, many do not initiate care or treatment. A study
in Cape Town found that only 62.5 % of recently
diagnosed patients received a CD4+ test result within
6 months; 66.7 % of those that were eligible for ART ini-
tiated treatment; and only 46.3 % of those not ART eli-
gible returned for a subsequent CD4+ test [14]. In a
study in rural Kwa-Zulu Natal, only 44.9 % of the HIV-
positive patients not yet ART eligible returned for subse-
quent CD4+ tests within 13 months [15]. To summarize,
whereas South Africa has the largest antiretroviral pro-
gram in the world [16], only 52 % of patients eligible for
ART are estimated to currently receive treatment [17].
These failures to engage patients in care are exacerbated
by further considering loss to follow-up after ART initi-
ation, which has long-lasting implications, worsening
outcomes for PLHIV, even if they return to care [18].
Interventions that link and retain patients in HIV care,
promote ART adherence, and encourage risk-reduction
behaviors in resource-limited settings are essential and
could substantially improve survival and prevent new
HIV infections [2, 19, 20]. We sought to identify strat-
egies that do not require extensive resources and could
realistically be implemented and supported by health
departments in sub-Saharan Africa. Among feasible
strategies that have the potential to improve care en-
gagement outcomes, particularly retention and adher-
ence, text messaging or short message service (SMS) and
personal support have both demonstrated promise and
could be economically feasible [20–22]. SMS cost 1 to 2
cents to send in bulk and are free for clients to receive.
Systematic reviews and meta-analyses have demon-
strated that the use of SMS for appointment reminders
have improved clinic attendance [23–25]. Additionally,
SMS interventions that included appointment re-
minders, laboratory result notifications, and medication
reminders have demonstrated promise in improving
ART initiation and retention in care, as well as ART ad-
herence in African settings [26–29]. One randomized
trial also demonstrated improved rates of viral suppres-
sion among those receiving weekly SMS [30].
Similarly, personal support interventions that focus on
professional case management or engaging peers or fam-
ily networks to provide encouragement and support to
remain in care and adhere to medications have demon-
strated promise [22]. A study in Kenya found that the
time to treatment failure was longer (reflective of better
retention and adherence to ART) for patients who
participated in support groups, received pharmacy
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counseling, or who had home visits [31]. Research in
Uganda suggests that care outcomes for those initiating
ART and those still pre-ART can be improved when pa-
tients receive treatment support [32, 33]. Furthermore,
recommendations from an international expert physician
panel now call for systematic monitoring of linkage and
retention in care, including the potential use of peer or
paraprofessional patient navigators to assist patients in
obtaining the care that they need [34]. Furthermore,
peer navigators are less costly than professional
personnel and may be more feasible to support in a
resource-constrained setting.
Given the promise of these intervention options, we
designed a cluster randomized trial to assess the efficacy
of an SMS intervention and a peer navigation interven-
tion to improve retention in care, timely linkage to care
and treatment, ART adherence, and prevention behav-




Using a cluster randomized trial at the level of the clinic,
we will evaluate the efficacy of employing two strategies
for enhancing linkage to and retention in clinical care,
ART adherence, and HIV preventive behaviors. A target
of 750 participants will be enrolled across 18 clinics in
the Moses Kotane and Rustenburg Sub-districts, Boja-
nala Platinum District, South Africa (Fig. 1). Clinics have
been randomized to one of three conditions: an SMS
intervention arm, a peer navigation (PN) arm that also
includes SMS, and a control condition. Clinics have been
randomized instead of individuals to avoid contamin-
ation of intervention across individuals within clinics
and to facilitate cooperation with clinic staff. Participant
outcomes will be monitored using both clinical record
extraction to document HIV care visits and services and
a series of interviewer-administered surveys at enroll-
ment (baseline assessment), 6 months after baseline, and
12 months after baseline.
Study setting
The North West Province has a population of just over
3.5 million people. The province is disproportionately
young, with 60 % of the population under the age of
34 years, with high rates of unemployment, poverty, and
low levels of educational attainment. Over 46 % of the
population is living in poverty compared to 39.9 % of
the national average [35]. The province has the fourth
highest HIV prevalence in the country: 13.3 % among
the general population [7] and 29.7 % among women in
antenatal services [36]. Within North West Province, the
Bojanala Platinum District, representing 37 % of the
overall provincial population, has an HIV prevalence of
35.0 % in the antenatal clinics [36], making it more heav-
ily affected than most other districts. Care in Bojanala
Platinum is provided by one provincial hospital, four dis-
trict hospitals, 13 community health centers, 104 pri-
mary health clinics, and numerous mobile health points.
Our study area was limited to two sub-districts, Moses
Fig. 1 Clinic allocation and participant enrollment. Notes: a Clinics were not eligible if they had a catchment area under 6,000 inhabitants,
inadequate patient load to ensure recruitment targets (40 new patients to patient registers in the first 4 months of 2014), were pilot clinic sites
(n = 4). b One clinic assigned to the SMS arm was under construction and has not opened as scheduled; as such, recruitment targets have been
adjusted at the remaining SMS clinics. cParticipants are eligible if they are 18 or older, diagnosed with HIV within the last 12 months, receiving
care at a study clinic, and willing to receive communication from study staff. Abbreviations used in the figure: No. = Number; PN = Peer
Navigation; SMS = Short Message Service (i.e., Text Message); SOC = Standard of Care
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Kotane and Rustenburg, and facilities included commu-
nity health centers and primary health clinics only.
Clinic selection and randomization
The 18 study clinics were selected from among 61 ART-
initiating clinics within the two study sub-districts. To
be eligible, a clinic could not be one of the four that had
participated in a pilot test of the interventions, had to
have a catchment area of 6,000 or more inhabitants, and
have adequate patient load to ensure recruitment targets
(defined as having 40 new individuals added to HIV pa-
tient care registers in the first 4 months of 2014). From
among the 24 clinics meeting these criteria, we excluded
one clinic that primarily served the mobile mining work-
force (estimated at over 90 % of their patient load), and
therefore was unlikely to retain patients. We also ex-
cluded one clinic that was not using patient registers,
which precluded establishing eligibility; one clinic that
was scheduled to close; and three clinics that were dis-
tant from study offices, complicating access and
supervision.
The 18 remaining clinics were randomized to one of
the three study arms, including seven to each interven-
tion condition and four to standard of care (Fig. 1). The
decision to randomize more clinics to intervention con-
ditions was based on agreements with the local govern-
ment partners at the district of health. We randomized
sites using methods described by Hayes [37]. We strati-
fied by sub-district and employed balanced (restricted)
randomization based on number of total monthly clinic
visits, number of HIV tests conducted in the previous
four months, number of patients on ART, and the func-
tionality of the monitoring and evaluation systems (in-
cluding record-keeping and supply chain management)
to ensure balance across the study arms.
Participant eligibility and recruitment
We will be enrolling 750 participants, with a target of 42
(range = 30-55) participants at each facility. All partici-
pants must be diagnosed with HIV within 1 year preced-
ing their enrollment. Participants must also be 18 years
or older, have access to a cellular telephone where they
are willing to receive automated text messages with
HIV-related content, and be willing and able to give in-
formed consent (not under the influence of illicit sub-
stances, or seemingly emotionally unstable at the time of
recruitment and enrollment). Written informed consent
will be obtained from all participants prior to enrollment
in the study.
We aim to recruit an equivalent number of men and
women and ensure that the sample has substantial rep-
resentation (minimum of 30 %) of clients who do not
yet quality for ART in order to assess the linkage and re-
tention for both clients who initiate ART and those who
do not. To accomplish this balance, recruitment will be
completed using two strategies. The first strategy in-
cludes recruiting clients who present at the clinic for
HIV testing and receive a positive diagnosis for the first
time, or those who are returning to collect their initial
CD4+ test results. Recruitment will be systematic: all of
those presenting for an HIV test or for an initial CD4+
test result will be approached by clinic staff about their
interest in participating in the study. We initially esti-
mated that between 50 % and 60 % of those recruited
during HIV testing would have an ART-qualifying CD4+
cell count at the time of recruitment [38]. Because the
national guidelines have recently changed to increase
qualifying CD4+ to 500 or less, it is more likely that 70
to 80 % of the individuals newly diagnosed after January
2015 will qualify for ART.
The second recruitment strategy includes identifying
patients from recent entries in the HIV care registers at
the clinic sites. This selection will also be systematic: we
will enumerate every male and female in the HIV care
registers and then systematically select men and women
at pre-determined intervals. The selection interval (for
example, every fourth woman listed) will differ by clinic
depending on the total number of male and female adult
registry entries. Because clinic registers are more
complete for ART patients than for pre-ART patients
(those not yet eligible for ART), we assume that the
large majority of patients recruited from the registers
(upwards of 90 %) will have qualified for ART. There-
fore, we aim to recruit 75 % of our participants through
the first strategy and 25 % of participants through the
second strategy to ensure that non ART-qualifying par-
ticipants are included.
Intervention
Two intervention strategies to increase retention in care
(primary outcome), as well as linkage to care, ART ad-
herence, and prevention behaviors (secondary outcomes)
will be compared to local standard of care (SOC). The
two intervention strategies that participants will receive
for the duration of 1 year are as follows: 1) an automated
SMS and 2) a peer-navigator (PN) model that also in-
cludes some automated SMS.
The first strategy includes three types of messages to
be sent to participants that will be delivered automatic-
ally from a central system based on their gender and
clinical/ART status recorded on registration and enroll-
ment forms and updated through clinical record extrac-
tion (Fig. 2). These three message types include the
following:
1. Behavioral Messages: These messages are sent on a
biweekly (every other week) basis, for a total of 26
messages during the 1-year study period. Behavioral
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messages are designed to address four themes: HIV
prevention (some of these messages are gender-
specific); engagement in care; medication adherence
(for those on ART) or awareness (for those not yet
eligible for treatment); and healthy living, which
includes messaging concerning alcohol/drug use,
social support and safe disclosure, and health/
nutrition.
2. Care Reminder Messages: Participants are sent a
message 3 days before any scheduled clinic visits,
whether for ART refills, CD4+ or HIV viral load
testing, or other routine care. Participants also
receive a reminder message if they have missed a
clinic visit by over 2 weeks, in line with South
African guidelines [13]. Patients receive up to 6
messages (bi-weekly) following a missed
appointment to encourage them to return to the
clinic. Additionally, when a client has failed to
present for a visit for 3 months, the study staff will
alert the clinic that a client has been lost to
follow-up.
3. Two-way Messages: These are automated biweekly
“check-in” messages that are sent from a central
system; they also record participant responses and
send a system alert to the team if a follow-up call to
the participant is needed. Two-way messaging serves
to maintain contact with the participant, provides a
means of retention in the study and in care, and also
is a probe to ensure that the participant is not
defaulting on care and treatment or experiencing
any difficulties that need to be addressed. The
participant receives a request to “reply 1 if you’re
good or 2 if you have a problem and need to talk.” If
the participant responds “2,” project staff will receive
an alert to call the client within the first business
day after receiving the notification. If the participant
does not respond to the check-in message within
24 hours, the participant receives the message a
second time. If the participant has not replied to
either message after 48 hours, the study staff will
receive an alert to call the client. When staff call for
either a “2” response or a non-response, they follow
a protocol for referrals and are trained not to offer
advice and counseling. Responding to two-way
messages is free of cost for participants.
The automated messaging system provides scheduled
delivery of messages via the CommConnect online plat-
form, part of the CommCare system developed by
Dimagi, Inc. The particular behavioral messages that a
participant receives are determined by gender and ART
status, as captured by study staff during enrollment. The
ART status classification is also linked to ongoing clinic
record extraction, so that if the ART status changes, so
does the message tree. Reminder messages are triggered
by a “date of next appointment” field, which is updated
during weekly chart extraction by study staff. If chart ex-
traction indicates that a participant has missed a visit by
over 2 weeks, a reminder is also sent. The CommCon-
nect system sends and receives messages free of cost to
participants. Even so, the study provides each participant
with 50 to 60 Rand of airtime on the participant’s cell
Fig. 2 Map of the principal data collection and intervention activities across three study arms. Abbreviations used in the figure: ART =
Antiretroviral Therapy; SMS = Short Message Service (i.e., Text Message)
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phone carrier of choice at enrollment and again at the 6-
month follow-up visit to ensure that participants are
comfortable using their phones for responding to study
check-in messages.
The second intervention strategy is predicated on rela-
tionship building and support with fellow patients. Spe-
cifically, the strategy makes use of peer navigators, who
work with participants to assess their barriers to reten-
tion in HIV care, ART adherence, and prevention of fur-
ther HIV transmission, and then aids participants in
developing plans and strategies for overcoming these
barriers. To be eligible to serve as a peer navigator, a
person must be HIV-positive, receiving care at a
government-run primary healthcare facility, and have
demonstrated commitment to adhering to medications
and clinical monitoring. Each navigator will assist ap-
proximately 10 participants (no more than 12) during
the study. Following an initial visit, navigators aim to
have at least one in-person meeting and one check-in by
SMS or phone with each participant each month (that
is, a minimum of two contacts per month for
12 months). This standardized contact schedule is
intended to serve as a minimum threshold. A navigator’s
work with a participant will often involve additional con-
tacts in the course of a month, such as offering to ac-
company a participant to their appointments (with
participant consent), assisting a participant with disclos-
ure of his or her HIV status to a family member or
friend, or conducting additional meetings by phone or
in-person to discuss emerging challenges and strategize
solutions.
Participants in the peer navigator condition will also
receive biweekly behavioral messages and appointment
reminders, which will be sent via the CommConnect
system according to the same schedule as used in the
SMS-only strategy. Following the pilot of these strategies
in four clinics, the study team resolved to include auto-
mated reminders and behavioral messages instead of
personalized reminders and behavioral messages sent by
the navigators to clients in the peer navigation arm. This
decision ensures better consistency of messaging be-
cause navigators in the pilot phase struggled to
personalize the sequencing of the various behavioral
messages while still adhering to standardized scripts for
each message. Additionally, investigators felt that auto-
mating the messages for clients in the PN arm would fa-
cilitate exploration of incremental effectiveness of the
two study interventions, with one (PN) building on the
other (SMS).
Peer navigators will meet weekly with their direct su-
pervisors and biweekly with the larger study team to dis-
cuss challenges being observed among participants, and
to develop potential approaches to overcome the ob-
served challenges. In addition, the supervisory team
meets weekly with study investigators to identify emer-
ging complex challenges with particular participants or
navigators, and to strategize solutions. Navigators also
have access to a “clinic liaison” at each clinic site. This
individual, usually one of the nurse providers, serves as a
primary point of contact between the study team and
clinic staff at a site. Navigators can refer their partici-
pants to the clinic liaison when, for example, they feel
that a participant has a problem that requires medical
attention or a referral for other medical or social
services.
Data collection procedures
Regardless of the intervention assignment, all partici-
pants, including those receiving services in the SOC
clinics, are asked to complete a baseline survey assess-
ment and provide contact information on the day that
enrollment occurs. Participants will be reassessed via
surveys during the 6-month and 12-month follow-ups.
Both baseline and follow-up assessments will capture in-
formation about (1) access to clinics and HIV care ser-
vices received in the 6 months preceding each
assessment, (2) self-reported assessments of ART adher-
ence (for participants on ART), and (3) self-reported
HIV risk behaviors and risk reduction practices (condom
use or partner reduction). The follow-up surveys also
capture (4) self-reported receipt of the intervention
components (for participants in the intervention arms)
and (5) self-reported satisfaction with SMS and peer
navigator services. We will also capture data related to
demographics, disclosure, anticipated stigma [39], alco-
hol use (AUDIT-C) [40, 41], and mental health (CESD-
10) [41, 42].
Data regarding clinical visits and care received will be
extracted from clinical files. Record extraction will occur
weekly for participants on ART, and every 2 weeks for
those not on ART, who are seen less frequently than the
ART patients. Study staff will capture details regarding
any visit that occurred since the last extraction, includ-
ing the visit date, HIV-related services received (for ex-
ample, medications), and any related CD4+ or HIV viral
load test results. All data collection forms and proce-
dures have been reviewed and approved by the Commit-
tee for Human Research at the University of California,
San Francisco (UCSF), the Human Subjects Division at
University of Washington, and the Human Sciences Re-
search Council (HSRC) Research Ethics Committee in
South Africa. The Policy, Planning, Research, Monitor-
ing and Evaluation Committee for the North West Pro-
vincial Department of Health also reviewed and
approved the protocol.
We will also conduct microcosting of the resources
needed to carry out the activities in all arms of the inter-
vention. Costing will include the following: 1) personnel
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(including fringe benefits), 2) recurring supplies and ser-
vices, 3) capital and equipment (for example, furniture
and computers), and 4) facility space. Intervention costs
will be assessed using a uniform cost data-collection
protocol to quantify resources used and associated costs
in each of the study arms. Data will be obtained through
administrative record reviews and administrative and
program staff interviews, supplemented by a staff time
study in order to distinguish pre-implementation and
implementation activities. Pre-implementation in-
cludes hiring, procurement, intervention development/
modification and training. Implementation includes
recruitment, intervention activities and supervision.
Nonresearch program management costs will be allo-
cated based on the period in which they occurred
(pre-implementation versus implementation).
Measures
Primary and secondary exposure and outcome measures
are included in Table 1. Primary exposure for the intent-
to-treat analysis is classified as the clinic randomization
arm: SMS intervention, PN intervention, and SOC. The
primary study outcome is retention in care, which is de-
fined for patients on ART as the proportion of patients
who have initiated ART who remain on treatment at 6
and 12 months and for patients who are not yet eligible
as the proportion of patients who undergo a repeat CD4
test at 6 months and 12 months after the initial CD4.
The secondary outcome of linkage to care is defined as a
patient undergoing CD4 staging or being assessed for
ART eligibility within 3 months of a positive diagnosis.
We will also monitor whether the participants are linked
to ART – that is, whether eligible participants receive
Table 1 Measures, data sources, and data collection schedules for protocol exposures and outcomes





Clinic where participant receives care Intake form Baseline
SECONDARY
EXPOSURE







Patients on or initiating ART who remain on treatment 6
and 12 months later (with documented receipt of treatment)
Intake and Record extraction Weekly (ART)
Survey data (self-report) 0, 6, and
12 months
Patients not ART eligible who have a repeat CD4 test at
6 months and 12 months after initial CD4
Intake and Record extraction Bi-weekly
(pre-ART)




Linkage to HIV care CD4 drawn and results available at clinic within 3 months
of testing HIV positive
Intake and Record extraction Weekly (ART) bi-
weekly (pre-ART)
CD4 result received within 3 months of testing HIV positive Survey data (self-report) 0 and 6 months
Patients eligible for ART who initiate treatment within
3 months of CD4 staging
Intake and Record extraction Weekly (ART)
Survey data (self-report) 0, 6, and
12 months
Adherence to ART Proportion taking 90 % and 100 % of pills in the past 30 days Survey data (self-report) 0, 6, and
12 months
Breaks in treatment during the previous six months (at least
4 days in a row)
Intake and Record extraction Weekly (ART)
Survey data (self-report) 0, 6, and
12 months
Proportion of days covered (# of dispensed days of
medication/# of days between refills)
Intake and Record extraction Weekly (ART)
Prevention
(transmission risk)
Number of unprotected sex acts by partner HIV status Survey data (self-report) 0, 6, and
12 months
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ART within 3 months of CD4 staging. The secondary
outcome of adherence is being assessed in three ways: as
a report of taking 90 % of the prescribed medication, as
no report or clinical record indicating gaps in treatment
of 4 or more days, and collection of the proportion of
days covered by medication dispensed. Finally, preven-
tion behavior is defined as the number of unprotected
sex acts by HIV partner status. All outcomes will be
measured using both clinical record extraction and self-
report; these two means of data collection will be com-
pared for accuracy (using clinical record extraction as
the gold standard).
Because the volume and intensity of the intervention
might vary, particularly in the PN arm, we will also cap-
ture intervention exposure or dosage as a secondary ex-
posure measure. Dose (minutes) of intervention received
will be used for per protocol analyses. In the PN arm,
this will include recording client data on frequency and
duration of in-person meetings and phone communica-
tions with the navigator. Delivery and response to SMS
messages for both intervention arms will be recorded
with a standard duration of exposure (for example,
30 seconds) for each message, including two-way messa-
ging. Any phone or in-person follow-up to SMS mes-
sages will be recorded separately. Secondary outcomes
include linkage to HIV care, adherence to medications,
and transmission risk behavior, as described in Table 1.
Analysis
Our preliminary analysis will include presentation of
participant demographic characteristics, service usage,
acceptability of intervention approaches and self-
reported sexual behavior within each of the three study
arms using descriptive statistics (one-way and cross-
tabular frequency tables and, for continuous variables,
measures of central tendency). Measures of variability
will account for repeated measures (multiple patients)
and consequent correlation of variables (clustering)
within each health facility. We will employ multiple im-
putation (MI) using chained equations to account for
missing data. This procedure assumes that incomplete
data arise from a missing-at-random (MAR) process,
under which missingness is random conditional on ob-
served covariables and observed outcomes rather than a
missing-completely-at-random (MCAR) mechanism
[43], thus making fewer assumptions about the nature of
the missing data. We will conduct sensitivity analysis
using weighted MI to evaluate the robustness of the
MAR assumption [44].
Our primary analyses will employ an intention-to-treat
(ITT) approach. We will employ logistic generalized esti-
mating equations (GEE) to compare patient retention
between intervention arms. We will also evaluate
secondary outcomes (linkage, adherence and prevention
behaviors) using an ITT analysis, as described above. We
will employ GEE rather than mixed effects models as
this approach allows us to estimate the effect of the
intervention at the level of the population, rather than at
the level of the individual. As our interventions will be
implemented at the level of the health system, it is im-
portant to estimate the effect of the intervention at the
level it is implemented [45]. Further, previous research
has suggested that adjustment for confounding can im-
prove the efficiency of estimates in the context of ran-
domized trials [46]. We will thus conduct sensitivity
analyses employing causal inference methods to account
for any imbalance in distribution of site- and individual-
level co-variables across study clinics. We will employ
targeted maximum likelihood estimation [47], which
allows estimation of both site- and individual-level
co-variables, to minimize bias and improve efficiency
of estimates of effect in the context of small sample
sizes [48].
Our secondary analyses will employ a per-protocol ap-
proach to evaluate differences in primary and secondary
outcomes. These analyses will resemble the intent-to-
treat analyses described above, with the difference that
individuals will be evaluated based on the number of mi-
nutes of intervention exposure they receive. As above,
these analyses will account for the clustering of results
within sites and include use of causal inference methods
to adjust for potential confounding. These analyses will
allow us to determine whether an observed effect of the
intervention is limited due to inadequate implementa-
tion and whether there is a needed dosage for the inter-
ventions to successfully impact outcomes. This will also
permit any accounting for contamination should an
SOC participant also receive services at an intervention
clinic (their intervention dosage can be included),
though we do not believe this will be common based on
distance between study clinics and experiences during
the pilot study. Our primary and secondary analyses will
employ robust standard errors as these are unbiased in a
setting where the coefficient of variation is less than 0.20
[49]. Our sensitivity analyses will include computation of
confidence intervals using bias-corrected sandwich esti-
mators [49–51]. Stata, version 13, will be used to man-
age data and conduct the primary and secondary
analyses; more complex sensitivity analyses will be con-
ducted using R.
Finally, for the cost analysis, we will use the observed
primary study outcome, retention in care to estimate the
cost per person retained in each intervention arm. Costs
will be summarized as total costs, cost per clinic and
cost per individual enrolled in each intervention arm.
Cost will also be broken out by pre- and post-
implementation periods in order to assess incremental
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costs associated with intervention scale-up (each add-
itional clinic added or individual enrolled). Efficiency will
be measured as the cost per additional person retained
in care for each arm of the study.
Sample size estimation
We aim to enroll 750 patients across the 18 participating
clinics, with the goal of ensuring that each of the 18
clinics has at least 30 participants, and no site more than
55 to guarantee a well-balanced sample and minimize
variability. We anticipate that approximately 20 % of the
sample will discontinue study participation, largely due
to extensive migration in the area. This estimate of attri-
tion is grounded in on our pilot experience, during
which 10 % of participants moved out of the area during
a 3-month observation period. We therefore anticipate
an evaluable sample of 600 participants over 1 year.
Under the assumption that only 50 % of participants in
the SOC clinics will remain in care [10, 38], this sample
size will provide 80 % power to observe a 20 % to 23 %
difference in patient retention at 12 months between the
PN and SOC or SMS and SOC arms and a 17 % to 20 %
difference between the PN and SMS arms. These esti-
mates assume a two-sided alpha of 0.05 and a coefficient
of variation of 0.15 to 0.20 or an intra-cluster correlation
of 0.0225 to 0.04 based on a review of the recent litera-
ture around sample size estimation in large cluster ran-
domized trials [52, 53].
Discussion
This trial will determine whether the use of SMS and
peer-navigation interventions in rural and peri-urban
clinics can improve engagement in HIV care and preven-
tion in South Africa, where scalable interventions are
sorely needed to improve current HIV outcomes. Both
interventions being explored were pilot tested and dem-
onstrated to be feasible to implement in similar low re-
source clinics in one of the study sub-districts (Moses
Kotane) prior to beginning the trial.
The SMS approach is now being used broadly for health
promotion given the ubiquitous presence of mobile
phones in South Africa and other sub-Saharan African
countries. Strategies utilizing cellular phones and other
mobile technologies to improve HIV outcomes in sub-
Saharan Africa are growing in number, particularly for ad-
herence reminders [21, 54]. Additionally, the South
African Government recently launched “MomConnect”, a
national initiative for pregnant women that aims to
improve access to maternal child health services by pro-
viding stage-based appointment reminders and well-baby
information SMS messaging [55], demonstrating both na-
tional interest and support for this approach to engage-
ment in care. The use of mHealth, particularly text
messaging technologies, does bring with it potential
challenges. In the pilot phase, participants were hesitant
to reply to messages from our service for fear of airtime
charge, despite assurances that all messaging to the pro-
ject was free. A number of participants reported either
losing their phone or having a break in coverage, necessi-
tating constant phone number confirmation and updating.
Finally, extensive efforts were needed to include all local
carriers on the messaging service free of charge to the
users, which required additional system programming. In
summary, whereas the promise of mobile phones for im-
proving HIV-related care outcomes is great, the need ex-
ists for additional research findings – showing not just
that reminders can improve retention in care, but that the
improved visit adherence will result in improved health
[23].
The peer-navigation approach has also gained traction
in recent years [21]. Though a peer-navigation interven-
tion equivalent to this protocol has not yet been
explored in South Africa to our knowledge, other treat-
ment supporter interventions have demonstrated poten-
tial, pointing to the need for support that goes beyond
mediation assistance to include emotional support and
encouragement [56]. A community-based PN model
may also be adapted to fit into the current policy climate
in South Africa. The government is currently rolling out
a new primary healthcare (PHC) re-engineering model,
which includes the deployment of a cadre of community
health workers to homes in their communities to moni-
tor health. These ward-based outreach teams (WBOTs)
are integrated into primary care facilities and support
priority clinic services in the community, including HIV
testing and HIV/TB care. Our team is exploring the pos-
sibility of integrating aspects of the peer navigation strat-
egy within the WBOT model, pending trial findings.
Another integration challenge that merits exploration in
optimizing any community-based health model is how
to incorporate the community-based work with services
located at the clinic. We found in our pilot phase that
integrating the peer navigators with clinical nursing and
counseling staff was not easy, despite the fact that the
clinic staff was pleased to have navigators working with
the clinic patients. Other challenges include intensive
training and supervision required to deploy and monitor
navigators, who need ongoing mentoring and debriefing,
particularly as they begin to traverse difficult barriers to
care with their clients, such as alcohol dependence or
food insecurity.
Although this trial will yield important data to drive
programming in South Africa and surrounding coun-
tries, some limitations exist to potential inferences and
the generalizability of the findings. Clinics selected for
the study come from both peri-urban and rural areas;
however, the selection area was limited to two sub-
districts and included only those clinics with sufficient
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patient load to warrant inclusion. As a result, findings
may not be generalizable to clients attending private
clinics, to residents of other provinces, or to residents of
large metropolitan centers or very rural areas where
clinics have limited HIV patient load. Additionally, while
trial participants are being systematically invited to par-
ticipate and should represent the current patients under-
going HIV testing and receiving services at the clinics,
the study population is not representative of the large
number of residents who do not present for testing,
which comprise approximately 35 % of the national adult
population [57].
Results will provide crucial information regarding the
efficacy of two complementary intervention strategies,
with the recognition that one intervention (SMS) is less
resource intensive but also less flexible in terms of the
patient barriers to care that it can address. This trial is
powered to compare retention outcomes at 12 months
between the SOC and both the SMS and the PN inter-
vention. This is an opportunity to estimate not only
intervention efficacy but also incremental efficacy from
the base SMS model to an enhanced peer navigation
model with patient reminders (which could be generated
either from an automated SMS system or directly from a
peer navigator). In the future, an exploration of targeted
interventions, or whether a more intensive intervention
(PN) could be targeted to the clients with more personal
barriers who require additional support, is needed. In
addition, knowledge of whether the less intensive model
of SMS would be sufficient for those who need re-
minders but do not experience major barriers, such as
fear of disclosure or substance use, is also needed.
Trial status
The trial began recruitment in one of two study sub-
districts on 20 October 2014 and in the second sub-
district on 26 January 2015. We aim to complete recruit-
ment by 5 January 2015.
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